Presented at: AACR 2022
Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis
Register here for download
You are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRelevant for
FixVUE, InSituPlex
Description Our poster describes the verification process to development specific pre-clinical mouse specific multiplexed immunofluorescence (mIF) assays. The use of pre-clinical mouse tumor models is widely used to demonstrate efficacy of novel immunotherapies, however a more comprehensive view of their tumor-immune compositions and their relevance to human tumors is needed. The use of specific mouse tissue phenotyping and mIF assays offer the unique advantage of preserving the architectural features of the tumor and revealing the spatial relationships between tumor cells and immune cells.
Authors
Yvette Cajigas, Alina Ainbinder, Gourab Chatterjee, Angela Vasaturo, Holger Weber, Erin Nicola, Mael Manesse, Kirsteen H. Maclean
Want to meet with us? Check out our upcoming events.
Related Content
Measuring concordance of CD8 and PD-L1 expression in Non-Small Cell Lung cancer between a novel multiplex immunofluorescence assay and a brightfield laboratory developed test
Presented at AACR 2020
Getting TiME on Your Side: Defining the future of precision medicine with advanced multiplexed immunofluorescence
Ultivue
A multiplex immunofluorescence assay to assess immune checkpoint inhibitor targeted CD8 activation and tumor co-localization in FFPE tissues Copy
High-multiplex automated staining and scanning workflow with Ultivue InSituPlex technology and the Olympus SLIDEVIEW VS200 slide scanner
Presented AACR 2020
Characterizing spatial distribution of immune-cell subsets in Nonalcoholic Steatohepatitis and Primary Sclerosing Cholangitis using a novel 12-plex Ultimapper ® kit
Presented at EASL 2021
